Search

Your search keyword '"Marescotti D"' showing total 33 results

Search Constraints

Start Over You searched for: Author "Marescotti D" Remove constraint Author: "Marescotti D"
33 results on '"Marescotti D"'

Search Results

9. AI-driven laboratory workflows enable operation in the age of social distancing.

10. Toxicological Assessment of Flavor Ingredients in E-Vapor Products.

11. Impact of aerosols on liver xenobiotic metabolism: A comparison of two methods of exposure.

12. Development of an Advanced Multicellular Intestinal Model for Assessing Immunomodulatory Properties of Anti-Inflammatory Compounds.

13. Comparison of the biological impact of aerosol of e-vapor device with MESH® technology and cigarette smoke on human bronchial and alveolar cultures.

14. An Intestine-on-a-Chip Model of Plug-and-Play Modularity to Study Inflammatory Processes.

15. In Vitro High-Content Imaging-Based Phenotypic Analysis of Bronchial 3D Organotypic Air-Liquid Interface Cultures.

16. Systems toxicology assessment of a representative e-liquid formulation using human primary bronchial epithelial cells.

17. Application of a multi-layer systems toxicology framework for in vitro assessment of the biological effects of Classic Tobacco e-liquid and its corresponding aerosol using an e-cigarette device with MESH™ technology.

18. GladiaTOX: GLobal Assessment of Dose-IndicAtor in TOXicology.

20. How complex should an in vitro model be? Evaluation of complex 3D alveolar model with transcriptomic data and computational biological network models.

21. A lung/liver-on-a-chip platform for acute and chronic toxicity studies.

22. In vitro systems toxicology-based assessment of the potential modified risk tobacco product CHTP 1.2 for vascular inflammation- and cytotoxicity-associated mechanisms promoting adhesion of monocytic cells to human coronary arterial endothelial cells.

23. The biological effects of long-term exposure of human bronchial epithelial cells to total particulate matter from a candidate modified-risk tobacco product.

24. A framework for in vitro systems toxicology assessment of e-liquids.

25. High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents (HPHC).

26. In Vitro Systems Toxicology Assessment of a Candidate Modified Risk Tobacco Product Shows Reduced Toxicity Compared to That of a Conventional Cigarette.

27. Systems biology approach for evaluating the biological impact of environmental toxicants in vitro.

28. High avidity binding to DNA protects ubiquitylated substrates from proteasomal degradation.

29. IFN-α boosts epitope cross-presentation by dendritic cells via modulation of proteasome activity.

30. Proteasome inhibitors induce the presentation of an Epstein-Barr virus nuclear antigen 1-derived cytotoxic T lymphocyte epitope in Burkitt's lymphoma cells.

31. Characterization of an human leucocyte antigen A2-restricted Epstein-Barr virus nuclear antigen-1-derived cytotoxic T-lymphocyte epitope.

32. Membrane binding and anticoagulant properties of protein S natural variants.

33. The Epstein-Barr virus nuclear antigen-1 promotes genomic instability via induction of reactive oxygen species.

Catalog

Books, media, physical & digital resources